Search results for " Pair 5"

showing 6 items of 16 documents

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion

2018

The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46%…

MaleBLOODDatabases FactualIMPACTCHROMOSOMECancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]medicine.medical_treatment[SDV]Life Sciences [q-bio]MedizinHematopoietic stem cell transplantationPROGNOSTIC SCORING SYSTEMGastroenterology0302 clinical medicineRecurrencehemic and lymphatic diseasesMDSCumulative incidenceLENALIDOMIDEIncidenceIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationHematologyMiddle AgedAllograftsTP53 MUTATIONSEUROPEAN-SOCIETY3. Good healthSurvival Rate030220 oncology & carcinogenesisWORKING PARTYChromosomes Human Pair 5FemaleChromosome DeletionLife Sciences & BiomedicineDEL(5Q)del (5q)medicine.drugAdultmedicine.medical_specialtyImmunology3122 CancersDisease-Free SurvivalSettore MED/01 - Statistica Medica03 medical and health sciencesSex FactorsAll institutes and research themes of the Radboud University Medical CenterInternal medicinemedicineHumansMARROW-TRANSPLANTATIONSurvival rateLenalidomideTransplantationScience & Technologybusiness.industryMyelodysplastic syndromesmedicine.diseaseAllogeneic stem cell transplantationTransplantationMyelodysplastic Syndromesbusiness030215 immunology
researchProduct

Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents

2017

Purpose Most anemic patients with non-deleted 5q lower-risk myelodysplastic syndromes (MDS) are treated with erythropoiesis-stimulating agents (ESAs), with a response rate of approximately 50%. Second-line treatments, including hypomethylating agents (HMAs), lenalidomide (LEN), and investigational drugs, may be used after ESA failure in some countries, but their effect on disease progression and overall survival (OS) is unknown. Here, we analyzed outcome after ESA failure and the effect of second-line treatments. Patients and Methods We examined an international retrospective cohort of 1,698 patients with non-del(5q) lower-risk MDS treated with ESAs. Results Erythroid response to ESAs was 6…

MaleCancer Research0302 clinical medicineRecurrenceRisk Factorshemic and lymphatic diseasesHydroxyureaCumulative incidenceTreatment FailureEnzyme InhibitorsLenalidomideAged 80 and overCytarabineAnemiaMiddle AgedThalidomideMelodysplastic syndromeSurvival RateLeukemia Myeloid AcuteOncologyInternational Prognostic Scoring System030220 oncology & carcinogenesisRetreatmentAzacitidineCyclosporineDisease ProgressionChromosomes Human Pair 5FemaleChromosome DeletionErythrocyte Transfusionmedicine.drugmedicine.medical_specialtyMelodysplastic syndrome erytropoiesis stimulating agents 5q-erytropoiesis stimulating agentsDecitabineAntineoplastic AgentsTretinoinDecitabineLower risk5q-Arsenic03 medical and health sciencesInternal medicinemedicineHumansImmunologic FactorsSurvival rateAgedAntilymphocyte SerumRetrospective StudiesLenalidomidebusiness.industryValproic AcidMyelodysplastic syndromesRetrospective cohort studymedicine.diseaseMyelodysplastic SyndromesHematinicsPhysical therapybusiness030215 immunology
researchProduct

Chromosome 5 abnormalities in acute lymphoblastic leukemia

1991

Abstract We report two cases of acute lymphoblastic leukemia with involvement of chromosome 5. One of them showed a del(5)(q13q33) in a 5-year-old boy who had previously received antineoplastic chemotherapy for an L1-ALL that had been diagnosed nine months before. The other one showed a t(5;7)(q12–13;q36) together with a t(8;14)(q24;q32) and a der(1) in a 66-year-old man with an L3-ALL. Both chromosome 5 aberrations are interpreted as evolutionary events. In the first case, it was secondary to chemotherapy treatment; in the second, an evolutionary chromosome rearrangement, considering the translocation between chromosomes 8 and 14 as the primary cytogenetic event.

MaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentLymphoblastic LeukemiaChromosome DisordersChromosomal translocationChromosomal rearrangementBiologyAcute lymphocytic leukemiaAntineoplastic chemotherapyGeneticsmedicineHumansMolecular BiologyChromosome AberrationsChemotherapyCytogeneticsChromosomePrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseChromosome BandingChild PreschoolKaryotypingImmunologyCancer researchChromosomes Human Pair 5Cancer Genetics and Cytogenetics
researchProduct

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

2012

Summary Lenalidomide is an effective drug in low-risk myelodysplastic syndromes (MDS) with isolated del(5q), although not all patients respond. Studies have suggested a role for TP53 mutations and karyotype complexity in disease progression and outcome. In order to assess the impact of complex karyotypes on treatment response and disease progression in 52 lenalidomide-treated patients with del(5q) MDS, conventional G-banding cytogenetics (CC), single nucleotide polymorphism array (SNP-A), and genomic sequencing methods were used. SNP-A analysis (with control sample, lymphocytes CD3+, in 30 cases) revealed 5q losses in all cases. Other recurrent abnormalities were infrequent and were not ass…

OncologyMalemedicine.medical_specialtyMultivariate analysisCD3Single Nucleotide Polymorphism ArrayBiologyPolymorphism Single NucleotideInternal medicinemedicineHumansImmunologic FactorsPlateletLenalidomideIn Situ Hybridization FluorescenceLenalidomideAgedAged 80 and overMyelodysplastic syndromesCytogeneticsKaryotypeHematologyMiddle Agedmedicine.diseaseChromosome BandingThalidomideTreatment OutcomeMyelodysplastic SyndromesImmunologyMutationbiology.proteinDisease ProgressionChromosomes Human Pair 5FemaleChromosome Deletionmedicine.drugBritish journal of haematology
researchProduct

Mapping and structure of DMXL1, a human homologue of the DmX gene from Drosophila melanogaster coding for a WD repeat protein.

2000

The DmX gene was recently isolated from the X chromosome of Drosophila melanogaster. TBLASTN searches of the dbEST databases revealed sequences with a high level of similarity to DmX in a variety of different species, including insects, nematodes, and mammals showing that DmX is an evolutionarily highly conserved gene. Here we describe the cloning of the cDNA and the chromosomal localization of one of the human homologues of DmX, Dmx-like 1 (DMXL1). The human DMXL1 gene codes for a large mRNA of 11 kb with an open reading frame of 3027 amino acids. The putative protein belongs to the superfamily of WD repeat proteins, which have mostly regulatory functions. The DMXL1 protein contains an exc…

Repetitive Sequences Amino AcidDNA ComplementaryMolecular Sequence DataBiologyConserved sequenceMiceGene mappingComplementary DNAGeneticsAnimalsDrosophila ProteinsHumansRadiation hybrid mappingAmino Acid SequenceDinucleotide RepeatsGeneIn Situ Hybridization FluorescenceGeneticsBase SequenceChromosome MappingProteinsbiology.organism_classificationOpen reading frameDrosophila melanogasterChromosomes Human Pair 5Insect ProteinsDrosophila melanogasterDrosophila ProteinGenomics
researchProduct

Near-Haploidy in a Malignant Sacrococcygeal Teratoma

1999

Cytogenetic analysis of a malignant sacrococcygeal teratoma in an adult patient revealed near-haploid (77%), near-diploid (19%), and polyploid (4%) cells. The near-haploid cells had a karyotype of 25,XX,der(5)t(5;7)(p15;p13),+7,der(9)t(6;9)(p21;q34),r(17)(p13q25) . In the near-diploid and polyploid cells identical copies of the structural chromosomal changes were found. Although some of the anomalies observed appear unique to this case, a common breakpoint in chromosome 6 was previously reported as specific in a subgroup of extragonadal germ cell tumors of adults.

SacrumCancer Researchmedicine.medical_specialtyPathologyNear-HaploidyExtragonadalChromosomal translocationHaploidyBiologyTranslocation GeneticPolyploidyFatal OutcomeGeneticsmedicineHumansMolecular BiologyAgedCoccyxPloidiesSpinal NeoplasmsfungiTeratomaCytogeneticsChromosome MappingChromosomeKaryotypeAnatomymedicine.diseaseDiploidyKaryotypingChromosomes Human Pair 5Chromosomes Human Pair 6FemaleGerm cell tumorsChromosomes Human Pair 9Tomography X-Ray ComputedSacrococcygeal teratomaChromosomes Human Pair 7Cancer Genetics and Cytogenetics
researchProduct